A Canadian Cohort Study to Evaluate the Outcomes Associated with a Multicenter Initiative to Reduce Antipsychotic Use in Long-Term Care Homes.

Nursing home inappropriate prescribing interRAI quality improvement quality indicators

Journal

Journal of the American Medical Directors Association
ISSN: 1538-9375
Titre abrégé: J Am Med Dir Assoc
Pays: United States
ID NLM: 100893243

Informations de publication

Date de publication:
06 2020
Historique:
received: 08 11 2019
revised: 25 03 2020
accepted: 06 04 2020
pubmed: 5 6 2020
medline: 24 6 2021
entrez: 5 6 2020
Statut: ppublish

Résumé

To evaluate the impact of a multicenter intervention to reduce potentially inappropriate antipsychotic use in Canadian nursing homes at the individual and facility levels. Longitudinal, population-based cohort study to evaluate the Canadian Foundation for Healthcare Improvement's Spreading Healthcare Innovations Initiative to reduce potentially inappropriate antipsychotic use in 6 provinces/territories. Adults in nursing homes in 6 provinces/territories in Canada between 2014 and 2016. The sample involved 4927 residents in 45 intervention homes and 122,570 residents in 1193 control homes in the first quarter of the study. Assessment data based on the Resident Assessment Instrument 2.0 were used in both settings to track antipsychotic use and to obtain risk-adjusters for a quality indicator on potentially inappropriate use. Quality improvement teams in participating organizations were provided with education, training, and support to implement localized strategies intended to reduce antipsychotic medication use in residents without diagnosis of psychosis. At the resident level, we found that the odds of remaining on potentially inappropriate antipsychotics were 0.75 in intervention compared with control homes after adjusting for age, sex, aggressive behavior, and cognition. These findings were evident within the pooled Canadian data as well as within provinces. At the facility level, the intervention homes had greater improvements in risk-adjusted quality indicator performance than the control homes, and this was true for the worst, median, and best-performing homes at baseline. There was no major change in the quality indicator for worsening of behavior symptoms. The Canadian Foundation for Healthcare Improvement intervention was associated with a reduction in potentially inappropriate antipsychotic use at both the individual and facility levels of analysis. This improvement in performance was independent of secular trends toward reduced antipsychotic use in participating provinces. This suggests that substantial improvements in medication use may be achieved through targeted, collaborative quality improvement initiatives in long-term care.

Identifiants

pubmed: 32493650
pii: S1525-8610(20)30321-2
doi: 10.1016/j.jamda.2020.04.004
pii:
doi:

Substances chimiques

Antipsychotic Agents 0

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

817-822

Informations de copyright

Copyright © 2020 AMDA — The Society for Post-Acute and Long-Term Care Medicine. Published by Elsevier Inc. All rights reserved.

Auteurs

John P Hirdes (JP)

School of Public Health and Health Systems, University of Waterloo, Waterloo, Ontario, Canada. Electronic address: hirdes@uwaterloo.ca.

Jennifer Major (J)

Canadian Foundation for Healthcare Improvement, Ottawa, Ontario, Canada.

Selma Didic (S)

Canadian Foundation for Healthcare Improvement, Ottawa, Ontario, Canada.

Christine Quinn (C)

Canadian Foundation for Healthcare Improvement, Ottawa, Ontario, Canada.

Lori Mitchell (L)

Winnipeg Regional Health Authority, Winnipeg, Manitoba, Canada.

Jonathan Chen (J)

School of Public Health and Health Systems, University of Waterloo, Waterloo, Ontario, Canada.

Micaela Jantzi (M)

School of Public Health and Health Systems, University of Waterloo, Waterloo, Ontario, Canada.

Kaye Phillips (K)

Health Standards Organization, Ottawa, Ontario, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH